Quantification of Lipid-Rich Core in Carotid Atherosclerosis Using Magnetic Resonance T2 Mapping Relation to Clinical Presentation

Joshua T. Chai, DPHIL,a Luca Biasiolli, DPHIL,a Linqing Li, PHD,b Mohammad Alkhalil, MD,a Francesca Galassi, PHD,a Chris Darby, MD,c Alison W. Halliday, MS,c Linda Hands, MS, Timothy Magee, MD,c Jeremy Perkins, MD,c Ed Sideso, MBBS,c Ashok Handa, MBBS,c Peter Jezzard, PHD,d Matthew D. Robson, PHD,a Robin P. Choudhury, DMAb

ABSTRACT

OBJECTIVES The aim of this study was to: 1) provide tissue validation of quantitative T2 mapping to measure plaque lipid content; and 2) investigate whether this technique could discern differences in plaque characteristics between symptom-related and non-symptom-related carotid plaques.

BACKGROUND Noninvasive plaque lipid quantification is appealing both for stratification in treatment selection and as a possible predictor of future plaque rupture. However, current cardiovascular magnetic resonance (CMR) methods are insensitive, require a coalesced mass of lipid core, and rely on multicontrast acquisition with contrast media and extensive post-processing.

METHODS Patients scheduled for carotid endarterectomy were recruited for 3-T carotid CMR before surgery. Lipid area was derived from segmented T2 maps and compared directly to plaque lipid defined by histology.

RESULTS Lipid area (%) on T2 mapping and histology showed excellent correlation, both by individual slices (R = 0.85, p < 0.001) and plaque average (R = 0.83, p < 0.001). Lipid area (%) on T2 maps was significantly higher in symptomatic compared with asymptomatic plaques (31.5 ± 3.7% vs. 15.8 ± 3.1%; p = 0.005) despite similar degrees of carotid stenosis and only modest difference in plaque volume (128.0 ± 6.0 mm³ symptomatic vs. 105.6 ± 9.4 mm³ asymptomatic; p = 0.04). Receiver-operating characteristic analysis showed that T2 mapping has a good ability to discriminate between symptomatic and asymptomatic plaques with 67% sensitivity and 91% specificity (area under the curve: 0.79; p = 0.012).

CONCLUSIONS CMR T2 mapping distinguishes different plaque components and accurately quantifies plaque lipid content noninvasively. Compared with asymptomatic plaques, greater lipid content was found in symptomatic plaques despite similar degree of luminal stenosis and only modest difference in plaque volumes. This new technique may find a role in determining optimum treatment (e.g., providing an indication for intensive lipid lowering or by informing decisions of stents vs. surgery). (J Am Coll Cardiol Img 2017;10:747-56) © 2017 by the American College of Cardiology Foundation. Published by Elsevier. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
lipid accumulation in the subendothelial space, following deposition and retention of apolipoprotein B-containing plasma lipoproteins, is a key process in the initiation and progression of atherosclerosis (1). Studies of ex vivo tissue in coronary (2) and carotid (3) atherosclerosis have demonstrated that plaques associated with thrombotic complications tend to contain larger lipid-rich necrotic core (LRNC), among other high-risk features such as thin fibrous cap, infiltration of inflammatory cells, and the presence of intraplaque hemorrhage (IPH). Therefore, 1 of the key goals in risk-stratifying vulnerable plaques has become the identification and quantification of LRNC using in vivo vessel wall imaging (4).

Although intensive lipid-lowering therapy can reduce total carotid vessel wall area (5), direct evidence of lipid removal has been sparse (6). One particular challenge is that evacuated lipids tend to be replaced by fibrous tissue (7), so that changes in total vessel wall area might be small or indiscernible by conventional imaging. As a new generation of lipid-lowering agents emerges (8,9), tools for robust quantitative assessment of plaque composition may facilitate refinement and stratification for patient selection, and allow better monitoring of treatment response.

Multicontrast cardiovascular magnetic resonance (CMR) is an established technique in plaque characterization (10). However, optimal techniques for quantitative LRNC detection on multicontrast CMR require injection of contrast media (6,11), and rely on tissue contrast relative to the adjacent sternocleidomastoid muscle, which depends on specific system and acquisition parameters. Moreover, multicontrast CMR suffers from blurring artifacts due to fast spin echo acquisitions (12) and needs extensive post-processing to coregister different contrast-weighted images and correct for image intensity variations (13).

We recently reported a quantitative CMR method to map $T_2$ relaxation times of plaque components on a voxel-by-voxel basis (14). Compared to multicontrast CMR, this novel approach is more objective, as it requires minimal user interaction in the analysis, and calculates real quantitative information on plaque composition. This raises the important possibility of in vivo plaque lipid quantification, at high resolution, across the entire plaque, and without the use of gadolinium-based contrast. In addition, plaque $T_2$ mapping addresses the need for an absolute physical parameter that can be standardized among different CMR systems and widely adopted in multicenter studies. Accordingly, here we sought: 1) to validate lipid quantification on carotid $T_2$ maps using histology gold standard; and 2) to evaluate its potential clinical application in relation to identifying recently unstable plaques.

### METHODS

#### STUDY POPULATION.
Ethical approval was obtained from National Research Ethics Services and local R&D committee. Forty patients awaiting carotid endarterectomy at Oxford University Hospitals NHS Trust were recruited from November 2011 to June 2014. Patients were scanned at the Oxford Acute Vascular Imaging Centre ≥24 h before surgery. Carotid plaques were collected at operation. Patients either had recently symptomatic (median time from index event 2 weeks) or asymptomatic carotid disease, with 50% to 99% stenosis according to NASCET (North American Symptomatic Carotid Endarterectomy Trial), or 70% to 99% according to ESCT (European Carotid Surgery Trial) criteria. Plaques were defined as culprit plaques where they were deemed to have given rise to either a minor cerebrovascular accident or a transient ischemic attack as assessed clinically and supported, where available, by brain magnetic resonance imaging or computed tomography imaging. Asymptomatic

---

### TABLE 1: Summary of Patient Characteristics Between Symptomatic and Asymptomatic Groups

| Characteristic | Symptomatic (n = 15) | Asymptomatic (n = 11) | Significance (p Value) |
|---------------|----------------------|-----------------------|------------------------|
| Male:female ratio | 2.75:1 | 2.67:1 | NS |
| Age, yrs | 73 (49-90) | 60 (43-89) | 0.046 |
| Hypertension | 14 (93.3) | 9 (81.8) | NS |
| Hypercholesterolemia | 12 (80.0) | 7 (63.6) | NS |
| Smoking | 7 (46.7) | 4 (36.4) | NS |
| Diabetes mellitus | 4 (26.7) | 4 (36.4) | NS |
| Previous CAD/CVA | 4 (26.7) | 6 (54.5) | NS |
| Aspirin/antiplaquette | 12 (80.0) | 8 (72.7) | NS |
| Statins | 14 (93.3) | 10 (90.9) | NS |
| Beta-blockers | 4 (26.7) | 3 (27.3) | NS |
| Calcium antagonists | 5 (33.3) | 3 (27.3) | NS |
| ACE inhibitors/ARBs | 6 (40.0) | 5 (45.5) | NS |
| Anticoagulation | 3 (20.0) | 0 (0) | NS |
| Right:left ratio | 6.5:1 | 1:1.2 | 0.038 |
| Stenosis, % | 81.3 ± 2.5 | 84.1 ± 3.0 | NS |

Values are median (range), n (%), or mean ± SEM.

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CAD = coronary artery disease; CEA = carotid endarterectomy; CV = cardiovascular; CVA = cerebrovascular accident; NS = not significant.
carotid plaques were those that had no documented clinical symptoms, but with an indication for carotid endarterectomy on the basis of percent stenosis.

**CMR PROTOCOL.** Patients were imaged on a Verio 3-T scanner (Siemens Healthcare, Erlangen, Germany) with a 4-channel phased-array carotid coil (Machnet, Roden, the Netherlands). Bright-blood time-of-flight (TOF) angiography of the carotid arteries was acquired to localize carotid bifurcation and lumen stenosis. Two-dimensional carotid T2 maps were generated from 14 images with echo time of 9 to 127 ms and repetition time of 2,000 ms, acquired using the multislice delay alternating with nutation for tailored excitation multiecho spin-echo (DANTE-MESE) sequence that combined black-blood preparation on the basis of nonselective DANTE pulse trains (15) with chemical-shift-selective fat saturated MESE. DANTE-MESE acquired 10 slices of 2 mm thickness each, covering 2 cm of the target carotid artery, in 8 min.

**DATA ANALYSIS.** DANTE-MESE image quality was assessed by an experienced reviewer (L.B.) who inspected the visibility of the carotid wall boundaries and rated them from 1 (poor) to 5 (excellent) according to standard procedures (16). Patients with overall quality <3 were excluded from the study.

T2 maps of the carotid arteries were generated voxel by voxel using monoexponential nonlinear fitting (14); lumen and external vessel boundaries were segmented using a validated semiautomated procedure (17). As reported previously, LRNC without IPH had shorter T2 than normal vessel wall and fibrous tissue, whereas with recent IPH into the core, T2 was longer than all other plaque components (14). Therefore, to take into account the minority of plaques with recent hemorrhage into the core, segmentation used dual T2 thresholds, a lower one (T2L) indicating the maximum T2 value associated with lipid alone and a higher one (T2H) above which IPH was recorded inside the plaque.
lipid core. Voxels with $T_2$ values below $T_{2L}$ or above $T_{2H}$ were thus classified as LRNC. Significant IPH ($T_2 > T_{2H}$) was defined as >5% of the total cross-sectional area. We also reported LRNC values on the basis of $T_{2L}$ alone, taking no account of hemorrhage.

To use the data most efficiently, segmentation performance was estimated by leave-1-out cross-validation. Lipid area (%) was computed for all possible combinations of $T_{2L}$ (range 30 to 50 ms) and $T_{2H}$ (range 70 to 120 ms) to find the pair of threshold values that achieved the optimal lipid segmentation on $T_2$ maps (i.e., the highest Pearson correlation coefficient $R$ against lipid quantification on histology).

All algorithms were implemented in Matlab (MathWorks, Natick, Massachusetts). Plaque type was also classified on the basis of $T_2$ mapping and TOF data (for identification of IPH and calcium) using the modified American Heart Association (AHA) scheme (10).

### HISTOLOGY

Carotid plaques were collected at endarterectomy and divided into 2 halves at the point of maximal stenosis: one half was snap-frozen and the other half processed for paraffin embedding. Paraffin sections (5 μm) were obtained at 1-mm intervals for histological examination using hematoxylin and eosin (Sigma-Aldrich, Poole, United Kingdom) and Masson’s trichrome (Merck-Millipore, Nottingham, United Kingdom), which identified collagen in the

### TABLE 2

| Histology | IV to V | VI | VII | VIII | Total |
|-----------|--------|----|-----|------|-------|
| IV to V   | 7      | 2  | -   | -    | 9     |
| VI        | 1      | 7  | -   | -    | 8     |
| VII       | 1      | -  | 4   | 1    | 6     |
| VIII      | -      | -  | -   | 3    | 3     |
| Total     | 9      | 9  | 4   | 4    | 26    |

Cohen’s $κ = 0.73$.

AHA = American Heart Association; CMR = cardiovascular magnetic resonance; TOF = time-of-flight.

### FIGURE 2

Quantification of Plaque Lipid

[T2 and segmented map of (A) a plaque with large lipid-rich necrotic core (LRNC) and (B) a plaque with multiple smaller lipid-rich pools, and their matching histology. LRNC was segmented from the $T_2$ map by thresholding (voxels with $T_2 < 42$ ms or $T_2 > 90$ ms). Right panels show 3-dimensional representations of plaque lipid distribution. Stacks of slices show lumen (red) and lipid (blue contours) segmented from $T_2$ maps (for illustration). The * signifies the lumen of the vessel. H&E = hematoxylin and eosin.]
fibrous tissue (green), as well as fibrin and erythrocytes from IPH (bright red). Lipid area without previous IPH appeared transparent or unstained in both hematoxylin and eosin and Masson’s trichrome stain.

Stained slides were scanned using the NanoZoomer (Hamamatsu Photonics, Hamamatsu City, Japan) virtual pathology system. Frozen sections (20 μm) at the mirror plane of division on 20 randomly selected plaques were obtained for Oil Red O (Sigma-Aldrich) staining to confirm lipid presence. Because IPH occurred exclusively inside, and as part of, the LRNC, the boundary of IPH against LRNC was often impossible to define on histology (Online Figure 1). The total histological lipid area (%) was hence calculated by combining lipid area with and without IPH. Total vessel cross-sectional area and lipid area (%) were obtained by manual segmentation using ImageJ, 64-bit, version 1.46r (National Institutes of Health, Bethesda, Maryland), as previously described (18). Plaque type was classified histologically using the AHA scheme (10).

LOCATION MATCHING. One investigator (L.B.) blinded to histology measured the distance from carotid bifurcation of T2 map locations and provided the corresponding T1-weighted images to a second investigator (J.T.C.) who obtained histology on the basis of the specific distance from bifurcation, and fine-tuned the exact matching location using local vessel morphology from the T1-weighted images provided.

SCAN-RESCAN REPRODUCIBILITY. Scan-rescan reproducibility of lipid quantification by T2 mapping was studied in 10 additional patients recruited on an unselected sequential basis. They were taken out of the scanner after the first scan and left sitting for 2 min before the second scan. Both scans acquired 10 contiguous slices to cover the entire plaque and assess the reproducibility of lipid area (%) per plaque.

STATISTICAL ANALYSIS. All statistical analyses are reported as mean ± SEM, unless otherwise stated; Student t tests and chi-square tests were performed. Lipid area correlation was calculated using both slice locations and plaques as the unit of analysis. Leave-1-out cross-validation was performed on the slice-by-slice dataset of independent lipid area measurements from T2 maps and histology.

RESULTS

PATIENT CHARACTERISTICS. CMR scan quality ≥3 was achieved for 26 of 40 plaques, 15 symptomatic and 11 asymptomatic. Patient characteristics are summarized in Table 1. There was no significant difference between genders, major cardiovascular risk factors or medications on admission between groups.

AHA CLASSIFICATION. Figure 1 shows how different plaque components can be identified on T2 maps. To evaluate how accurately T2 mapping can determine plaque types, we used the modified AHA plaque classification system and compared this directly against histological classification. Table 2 shows plaque types determined by T2 map (+ TOF) against histology, which showed good agreement (80.8%) between the 2 methods (Cohen’s κ = 0.73).

LIPID QUANTIFICATION. We next used T2 maps to quantify plaque lipid content (Figure 2). Varying according to the length of each carotid atherosclerotic lesion, an average of 2.3 slices of T2 map data were obtained per plaque, yielding 60 matched slices. Using leave-1-out cross-validation, the combination T2L = 42 ms and T2H = 90 ms produced maximum R = 0.85 (p < 0.001) against lipid area (%) measured...
on histology (Figure 3A), thus achieving optimal $T_2$ map segmentation for lipid quantification. Additionally, root mean square error was minimum (10.5%) and Bland-Altman analysis confirmed a high degree of agreement between $T_2$ maps and histology, with only 0.03% underestimation on $T_2$ maps (Figure 3B).

For technical validation, we made multiple comparisons of $T_2$ maps and tissue stains per slice. However, for biological applications, the unit of analysis would be per plaque rather than per slice. Grouping individual slice locations from each plaque on the same scatter plot, we showed that data points from the same plaque were relatively closely clustered together (Figure 4A), indicating that slices from the same plaque tend to contain similar proportions of lipid. Furthermore, comparing the average lipid area (%) per plaque measured by $T_2$ map and by histology maintained a strong correlation ($R = 0.83, p < 0.001$) (Figure 4B).

**SYMPTOMATIC VERSUS ASYMPTOMATIC.** We then tested using $T_2$ mapping whether LRNC size varied between different clinical presentations. Symptomatic plaques were found to have significantly higher lipid area (%), compared to asymptomatic plaques ($31.5 \pm 3.7\%$ vs. $15.8 \pm 3.1\%; p = 0.005$, relative difference 99.4%) (Figure 5A). This was despite similar degree of carotid stenosis ($81.3 \pm 2.5\%$ symptomatic vs. $84.1 \pm 3.0\%$ asymptomatic; $p = NS$), and only a modest difference in terms of plaque volume ($128.0 \pm 6.0 \text{mm}^3$ symptomatic vs. $105.6 \pm 9.4 \text{mm}^3$ asymptomatic; $p = 0.04$; relative difference - 21.2%).

In addition, using an established definition of large LRNC as $\geq 25\%$ of cross-sectional area (3,19), we further confirmed that symptomatic plaques had significantly larger LRNC using $T_2$ mapping alone ($p = 0.003$) (Figure 5B). Finally, the receiver-operating characteristic (ROC) area under the curve was 0.79 ($p = 0.01$), indicating that lipid quantification by $T_2$ mapping has a good ability to discriminate between symptomatic and asymptomatic plaques in our clinical cohorts. ROC analysis determined the optimal cutoff for LRNC between clinical cohorts to be $\simeq 25\%$ (sensitivity = 67\%, specificity = 91\%) (Figure 5C).

**INTRAPLQUE HEMORRHAGE.** To clarify whether the inclusion of IPH in our calculation with a second $T_2$ threshold had influenced our results, we examined the prevalence of IPH and its contribution to the total lipid area (%). Sixteen of the total 60 slices contained significant (>5\%) IPH. Of these, only 7 had IPH infiltrating >50% of the lipid core. Thus IPH made a relatively minor contribution to the total lipid measurement. Figure 6 shows the copresence of IPH and lipid-filled macrophage foam cells. We then reanalyzed our data using a single $T_2$ threshold of <42 ms for segmentation and lipid area calculation, by so doing effectively excluded IPH (long $T_2$) as part of the LRNC in $T_2$ map segmentation, yet the strength of correlation was similar to our dual $T_2$ threshold approach ($R = 0.79$ vs. 0.85). In fact, if we excluded those 7 slices with large (>50\%) IPH from the cohort, the correlation of the remaining 53 slices using a single threshold (<42 ms) approach went back to $R = 0.85$.

**SCAN-RESCAN REPRODUCIBILITY.** One of the 10 carotid plaques scanned to evaluate reproducibility was rejected due to low image quality during rescanning. For the remaining 9 plaques, lipid core measurements ranged from 5.7% to 36.6% with a mean of 20.3%. The scan-rescan reproducibility was excellent (intraclass correlation coefficient = 0.89; 95% confidence interval: 0.59 to 0.98; coefficient of variation = 8.9% [plaque-by-plaque comparison]).
DISCUSSION

This work makes 2 principal findings. First, in vivo T2 mapping, on a voxel-by-voxel basis, and at high resolution, enables accurate and highly reproducible quantification of plaque lipid, validated with histology. Second, lipid quantification by T2 mapping can distinguish recently symptomatic plaques with high sensitivity and specificity.

Deposition and retention of cholesterol-rich lipoproteins is a cardinal feature of atherosclerosis, occurring from the earliest foam cell lesions through to the complex plaques of advanced disease. Where the rate of deposition exceeds the rate of clearance, cholesterol and cholesterol derivatives can accumulate within the plaque. The presence of a large LRNC (especially associated with a thin overlying fibrous cap) has been associated with high risk of rupture and atherothrombotic complications (3). Furthermore, the presence of lipid in the plaque is a driver of local inflammation (20) and altered gene expression (21).

Because of these central roles, quantification of plaque lipid has been a key aim of various atherosclerosis imaging techniques such as intravascular ultrasound (22), near infrared spectroscopy (23), cardiac computed tomography (24), and vascular magnetic resonance imaging (11).

Since the first description of Toussaint et al. (25), magnetic resonance techniques have been applied for the detection of LRNC (26,27). However, a significant limitation of this approach is low sensitivity, such that LRNC can be detected only in a minority of plaques with relatively large coalesced lipid pools. In a survey of 100 patients with varying extents of coronary atheroma, only 20% had a discernable LRNC in the carotid artery on multicontrast CMR (28). Reliable detection of small scattered pools of lipid depends on image resolution and signal-to-noise ratio in both T2 mapping and multicontrast CMR. The main advantage of T2 mapping is to provide quantitative information, on a per-voxel basis, using direct measurement of an absolute physical property of plaque.

**FIGURE 5** Symptomatic Plaques Contain More Lipid Than Asymptomatic Plaques

(A) Symptomatic plaques contained significant more lipid than asymptomatic plaques (31.5 ± 3.7% vs. 15.8 ± 3.1%; p = 0.005) despite similar degree of luminal stenosis. (B) Chi-square test using an established cutoff of >25% to define a large lipid-rich necrotic core (LRNC) showed similar results. (C) Receiver-operating characteristic curve analysis showed that T2 mapping has a fair to good ability to discriminate between symptomatic and asymptomatic plaques. *p < 0.05, **p < 0.01. AUC = area under the curve.
components. Our approach to lipid quantification is therefore more objective and less dependent on acquisition parameters than multicontrast CMR, which relies on relative signal intensities for plaque segmentation. In addition, T₂ mapping does not suffer from blurring artifacts intrinsic to fast spin echo acquisition (12), nor does it require image coregistration and intensity correction (13). Finally, it is more time efficient (one-fifth of the time required by multicontrast protocol for LRNC quantification) (6,11) and without exposing patients to a gadolinium-based contrast agent. Because the validation required tissue obtained by endarterectomy (undertaken for severe stenotic disease), our series contains relatively large lesions (of AHA classes IV to VIII on histology). In this context, plaque lipid was detectable in virtually all cases.

Atherosclerosis regression is a term used to denote favorable remodeling of plaque, for instance in response to aggressive reduction in plasma level of atherogenic lipoproteins (29). Normalization of plasma lipid profile in genetically modified hyperlipidemic mice with atherosclerosis leads to marked loss of plaque lipid and deposition of fibrous tissue (7), with similar changes inferred in man (30). This has important implications in the clinic because some anti-atherosclerotic agents may well change plaque lipid content, without necessarily altering total plaque volume. This suggests that accurate quantification of plaque lipid might prove useful for patient stratification and selection for intensive lipid lowering therapies or monitoring of response to treatment, including in clinical trials. The technique validated here shows excellent scan-rescan reproducibility and would be well suited to serial application in lipid-intervention trials. This may be important since several new classes of lipid lowering therapies have been developed, including lipoprotein(a) and apolipoprotein B antisense, microsomal triglyceride transfer protein inhibition, cholesteryl ester transfer protein inhibitors,

![FIGURE 6](image-url)
and proprotein convertase subtilisin/kexin type 9 inhibitors, but considerations of cost effectiveness, mode of administration, and, in some cases, potential toxicity mean that they are unlikely to be used indiscriminately in patients with atherosclerotic disease. Methods for rational stratification are therefore needed.

Applying $T_2$ mapping in our different clinical cohorts, we found that despite having similar degree of carotid stenosis, and only a modest 21.2% difference in terms of plaque volume, symptomatic plaques had 99.4% larger LRNC than asymptomatic plaques. ROC analysis confirmed our technique having good ability to distinguish between symptomatic and asymptomatic plaques with optimal LRNC cutoff at 25% of the cross-sectional area, in agreement with large-scale histological series in both carotid (3) and coronary (31) locations. The ability to accurately quantify plaque lipid might also prove useful in informing decisions between carotid surgery and stenting because a large LRNC is considered to be an important factor determining the amount of stent-related downstream debris (32) and has been shown to increase risk of stroke following carotid stenting (32,33). Three-dimensional rendering of lipid distribution in relation to local vessel anatomy using quantitative $T_2$ mapping data may assist interventional procedural planning to minimize such risks (Figure 2, right panels).

**STUDY LIMITATIONS.** The main limitation of our method is the sensitivity to motion artifacts, a fact reflected in the scan rejection rate (35%), which is comparable to that of multicontrast CMR (30%) (11). Strategies for motion correction are currently being actively pursued. Another limitation is the challenge to effectively exclude IPH as part of the LRNC measurement. By either method, the strength of correlation was similar ($R = 0.79$ vs. $0.85$). This demonstrated empirically that $T_2$ mapping does track plaque lipid content accurately, whether or not IPH is considered as part of the LRNC calculation. Finally, this histological validation study has a relatively small number of subjects and CMR slices. To utilize the available data most efficiently, we employed leave-1-out cross-validation to test the performance of our $T_2$ segmentation model on data that were not used to build it.

**CONCLUSIONS**

We provided histological validation of a new in vivo multislice $T_2$ mapping technique for quantification of plaque lipid content. Not only can $T_2$ mapping distinguish between symptomatic and asymptomatic plaques on the basis of their lipid content, but we showed that despite similar degree of luminal stenosis and only modest difference in plaque volume, symptomatic plaques contained nearly double the lipid content compared with asymptomatic plaques on $T_2$ maps. This technique may be of value in patient selection and evaluating response to new anti-atherosclerotic treatment and interventions.

**ACKNOWLEDGMENTS** The authors acknowledge the support of the BHF Centre of Research Excellence, Oxford. This work was supported by the NIHR Oxford Biomedical Research Centre and the British Heart Foundation Centre of Research Excellence, Oxford.

**ADDRESS FOR CORRESPONDENCE:** Prof. Robin P. Choudhury, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, John Radcliffe Hospital, Headley Way, Level 6, West Wing, Oxford OX3 9DU, United Kingdom. E-mail: robin.choudhury@cardiov.ox.ac.uk.

**PERSPECTIVES**

**COMPETENCY IN MEDICAL KNOWLEDGE:** Quantitative $T_2$ mapping is a novel technique in characterization of carotid atherosclerotic plaques. Using histological validation, this study demonstrated its ability to differentiate various plaque components, with an emphasis on lipid quantification. Symptom-related plaques were shown to contain significantly more lipid despite similar degree of luminal stenosis and only modest difference in plaque volume compared with asymptomatic plaques. $T_2$ mapping is accurate and reproducible; it is an alternative technique to the conventional multicontrast approach, which may be of value in future lipid intervention trials and cardiovascular risk stratification.

**TRANSLATIONAL OUTLOOK:** Technical improvements are actively pursued, to reduce imaging time by compressed sensing, increase spatial resolution coverage and signal-to-noise ratios by better multichannel coils, and reduce motion artifacts by the development of image navigator-based approaches. How the changes in the size of lipid-rich core in vulnerable plaques, as an imaging biomarker, translate to the modification of cardiovascular risks remain to be elucidated.
REFERENCES

1. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551–61.

2. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 2002;15:439–46.

3. Redgrave JNE, Lovett JK, Gallagher PJ, Rothwell PM. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford Plaque Study. Circulation 2006;113:2320–8.

4. Underhill HR, Hatsukami TS, Fayad ZA, Foster V, Yuan C. MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol 2010;7:165–73.

5. Corti R, Foster V, Fayad ZA, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002;106:2884–7.

6. Zhao XG, Dong L, Hatsukami T, et al. MR imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. J Am Coll Cardiol Img 2011;4:977–86.

7. Rong JX, Li J, Reis ED, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001;104:2447–52.

8. Robinson JG, Farnier M, Krentf MP, et al. Efficacy and safety of atorvastatin in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489–99.

9. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500–9.

10. Cai J, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classification of human carotid atherosclerotic lesions with in vivo multi-contrast magnetic resonance imaging. Circulation 2002;106:1368–73.

11. Cai J, Hatsukami TS, Ferguson MS, et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 2005;112:3437–44.

12. Biasioli L, Lindsay AC, Choudhury RP, Robson MD. Loss of fine structure and edge sharpness in fast-spin-echo carotid wall imaging: measurements and comparison with multiple-spin-echo in normal and atherosclerotic subjects. J Magn Reson Imaging 2011;33:1136–43.

13. Kerwin W, Xu D, Liu F, et al. Magnetic resonance imaging of carotid atherosclerosis: plaque analysis. Top Magn Reson Imaging 2007;18:371–8.

14. Biasioli L, Lindsay AC, Chai JT, Choudhury RP, Robson MD. In-vivo quantitative T2 mapping of carotid arteries in atherosclerotic patients: segmention and T2 measurement of plaque components. J Cardiovasc Mag Reson 2013;15:69.

15. Li L, Chai JT, Biasioli L, et al. Black-blood multicontrast imaging of carotid arteries with DANTE-prepared 2D and 3D MR imaging. Radiology 2014;273:560–9.

16. Cai J, Mitsumori LM, Ferguson MS, et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 2001;104:2051–6.

17. Wang Q, Robson MD, Francis JM, et al. Accuracy of quantitative MR vessel wall imaging applying a semi-automated gradient detection algorithm—a validation study. J Cardiovasc Mag Reson 2004;6:895–907.

18. Choudhury RP, Rong JX, Trogan E, et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004;24:1904–9.

19. Virmani R, Kolodgie F, Farb A, Schwartz S. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262–75.

20. Gronholt ML, Nordestgaard BG, Bentzon J, et al. Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. J Vasc Surg 2002;35:137–45.

21. Yehuda H, Szuchman-Sapir A, Khatib S, Musa R, Tamir S. Human atherosclerotic plaque macrophage-like cells. Atherosclerosis 2011;218:222–30.

22. Briguet A, Douek PC. Atherosclerotic plaques: nature and timing of ischemic symptoms: the Ox-CAMPSA study. Circulation 2006;113:1331–3.

23. Sanon S, Dao T, Sanon VP, Chilton R. Imaging of vulnerable plaques using near-infrared spectroscopy for risk stratification of atherosclerosis. Curr Atheroscler Rep 2013;15:304.

24. Schmid M, Pflederer T, Jang IK, et al. Relationship between degree of remodeling and CT attenuation of plaque in coronary atherosclerotic lesions: an in-vivo analysis by multi-detector computed tomography. Atherosclerosis 2008;197:457–64.

25. Toussaint JF, LaMuraglia GM, Southern JF, Foster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 1996;94:932–8.

26. Lindsay AC, Biasioli L, Lee JMS, et al. Plaque features associated with increased cerebral infarction after minor stroke and TIA: a prospective, case-control, 3-T carotid artery MR imaging study. J Am Coll Cardiol Img 2012;5:388–96.

27. Serfaty JM, Chaabane L, Tabib A, Chevalier JM, Bruget A, Douek PC. Atherosclerotic plaques: classification and characterization with T2-weighted high-spatial-resolution MR imaging—an in vitro study. Radiology 2001;219:403–10.

28. Kylintreas I, Shirodaria C, Lee JMT, et al. Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: relationships with coronary disease severity. J Cardiovasc Mag Reson 2013;15:61.

29. Mizoguchi R, Bowers M, Harnen P, Loo R, LaDisa JF Jr. Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. J Cardiovasc Mag Reson 2011;13:37.

30. Zhao XG, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001;21:1623–9.

31. Mizoguchi R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47:C13–8.

32. Yoshimura S, Yamada K, Kawasaki M, et al. High-intensity signal on time-of-flight magnetic resonance angiography indicates carotid plaques at high risk for cerebral embolism during stenting. Stroke 2011;42:3132–7.

33. Biasi GM, Froio A, Dietrich EB, et al. Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study. Circulation 2004;110:756–62.

34. Chu B. Hemorrhage in the atherosclerotic carotid plaque: a high-resolution MRI study. Stroke 2004;35:1079–84.

35. Chai JT, Digby JE, Ruparelia N, Jefferson A, Handa A, Choudhury RP. Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells. PLoS One 2013;8:e62934.

KEY WORDS atherosclerosis, cardiovascular magnetic resonance, carotid, lipid, plaque, T2 mapping

APPENDIX For an expanded Methods section and a supplemental figure, please see the online version of this article.